Rakesh Popat

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 18

Top Topics

Respiratory Syndrome Coronavirus

Multiple Myeloma

Top Venues

British journal of haematology

Leukemia & lymphoma

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

American journal of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Edward Robert Scheffer Cliff, Gemma Reynolds, Rakesh Popat, Benjamin W Teh, Aaron S Kesselheim, Ghulam Rehman Mohyuddin
Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Sarah Leong, Ho Pui Jeff Lam, Zoe Kirkham, Rakesh Popat
Antibody drug conjugates for the treatment of multiple myeloma. American journal of hematology (2022)
Marquita Camilleri, Maria Cuadrado, Elizabeth Phillips, William Wilson, Richard Jenner, Gavin Pang, Sumaiya Kamora, Matthew Streetly, Rakesh Popat, Ceri A Bygrave, Roger Owen, James Cavenagh, Mike Chapman, Jonathan Sive, Lydia Eccersley, Michael Sheaff, Reuben Benjamin, Karthik Ramasamy, Curly T C M Morris, Andres Virchis, Selina J Chavda, Laura Clifton-Hadley, Marie Anne Scully, Kwee L Yong
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. British journal of haematology 193 (4) (2021)
Monica Ziff, Gabrielle Lawson, Dunnya De-Silva, Simon Cheesman, Charalampia Kyriakou, Shameem Mahmood, Xenofon Papanikolaou, Neil Rabin, Sajitha Sachchithananthan, Jonathan Sive, Ashutosh D Wechalekar, Kwee L Yong, Rakesh Popat
Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set. Leukemia & lymphoma 62 (5) (2021)
Rakesh Popat, Nicholas Counsell, Ruth de Tute, Dunnya De-Silva, Elizabeth H Phillips, Jamie D Cavenagh, Toyin Adedayo, Nivette Braganca, Claire Roddie, Matthew Streetly, Steve Schey, Mickey B C Koh, Josephine Crowe, Treen C Morris, Curly T C M Morris, Paul Smith, Laura Clifton-Hadley, Neil Rabin, Roger Owen, Kwee L Yong, null null
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial. British journal of haematology 193 (3) (2021)
Marquita Camilleri, Thomas McGrath, William Wilson, Stuart J Ings, Jacqueline Horder, Fiona Newrick, Jonathan Sive, Xenofon Papanikolaou, Rakesh Popat, Charalampia Kyriakou, Kwee L Yong, Neil Rabin
Impact of COVID-19 on peripheral blood stem cell mobilization for myeloma patients. Leukemia & lymphoma 62 (12) (2021)
Selina J Chavda, Rachael Pocock, Simon Cheesman, Kyung-Min Lee, Emma Dowling, Daniel J B Marks, Charalampia Kyriakou, Lydia Lee, Jonathan Sive, Ashutosh Wechalekar, Neil Rabin, Kwee L Yong, Rakesh Popat
Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations. British journal of haematology 190 (5) (2020)
Annabel McMillan, Dana Warcel, Rakesh Popat
Antibody-drug conjugates for multiple myeloma. Expert opinion on biological therapy 21 (7) (2020)
Curly T C M Morris, A John Ashcroft, Guy Pratt, Rakesh Popat, Karthik Ramasamy, Martin F Kaiser, Matthew Jenner, Sarah Henshaw, Rachel Hall, Jonathan Sive, Simon Stern, Matthew Streetly, Ceri A Bygrave, Richard Soutar, Neil Rabin, Graham H Jackson, null null
Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. British journal of haematology 190 (2) (2020)
Olga Salamero, Pau Montesinos, Christophe Willekens, José Antonio Pérez-Simón, Arnaud Pigneux, Christian Récher, Rakesh Popat, Cecilia Carpio, César Molinero, Cristina Mascaró, Joaquim Vila, M Isabel Arévalo, Tamara Maes, Carlos Buesa, Francesc Bosch, Tim C P Somervaille
First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 38 (36) (2020)
Marquita Camilleri, Jonathan Sive, William Wilson, Gavin Pang, Richard Jenner, Elizabeth Phillips, Rakesh Popat, Karthik Ramasamy, Ceri A Bygrave, Tushhar Dadaga, Matthew Streetly, James Cavenagh, Mike Chapman, Sally F Barrington, Lucy Pike, Roger Owen, Laura Clifton-Hadley, Kwee L Yong
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial. British journal of haematology 192 (1) (2020)
Richa Manwani, Shameem Mahmood, Sajitha Sachchithanantham, Helen J Lachmann, Julian D Gillmore, Kwee L Yong, Neil Rabin, Rakesh Popat, Charalampia Kyriakou, Sarah Worthington, Faye A Sharpley, Mark Smith, Raakhee Shah, Simon Cheesman, Philip N Hawkins, Ashutosh D Wechalekar
Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. British journal of haematology 187 (5) (2019)
Dima El-Sharkawi, Chin-Hin Ng, Elspeth M Payne, Kwee L Yong, Kirit M Ardeshna, Asim Khwaja, William Townsend, Rakesh Popat
Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials. British journal of haematology 185 (2) (2018)
Selina J Chavda, Paul M Maciocia, Pavlina Mesiri, Nicholas Counsell, Jaimal Kothari, Antonia Bird, Ciaran Mariner, Anastasia Chew, Katherine Clesham, Sally Moore, Laura Percy, Ali Rismani, Shirley D'Sa, Neil Rabin, Rakesh Popat, Kwee Yong
A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1. British journal of haematology 185 (2) (2018)
Esther H L Chan, Dunnya De-Silva, Adeline H F Lin, Neil Rabin, Ashutosh Wechalekar, Rakesh Popat, Wee Joo Chng, Kwee L Yong
Clinical benefit of depth of response for relapsed/refractory multiple myeloma patients treated on clinical trials: retrospective analysis from two tertiary centres. British journal of haematology 186 (1) (2018)
Rakesh Popat, Sarah R Brown, Louise Flanagan, Andrew Hall, Walter Gregory, Bhuvan Kishore, Matthew Streetly, Heather Oakervee, Kwee Yong, Gordon Cook, Eric Low, Jamie Cavenagh, null null
Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial). British journal of haematology 185 (3) (2018)
Oliver C Cohen, Nicholas Counsell, Neil Rabin, Rakesh Popat, Roger G Owen, Bilyana Popova, Oliver Schofield, Laura Clifton-Hadley, Janet Lyons-Lewis, Andy Rawstron, Christopher Spence, Ruth M de Tute, Derralynn Hughes, Sally Moore, Paul Smith, Kwee L Yong
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse. British journal of haematology 185 (5) (2018)
Rakesh Popat, Emma Dowling, Sufyan Achhala, Devanshi Pandit, Neil Rabin, Charalampia Kyriakou, Stephen Mackinnon, Kwee Yong, Ashutosh Wechalekar
Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services. British journal of haematology 182 (6) (2017)